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Background: There is considerable interest in the role of neuroinflammation in the pathogenesis of 
Alzheimer’s disease. Evidence from observational studies suggests an association between cytokine 
concentrations and Alzheimer’s disease. However, establishing a causal role of cytokine concentrations 
on risk of Alzheimer’s disease is challenging due to bias from reverse causation and residual 
confounding.  
Methods: We used two-sample MR to explore causal effects of circulating cytokine concentrations on 
Alzheimer’s disease and vice versa, employing genetic variants associated with cytokine concentrations 
(N=8,293) and Alzheimer’s disease (71,880 cases / 383,378 controls) from the largest non-overlapping 
genome-wide association studies (GWAS) of European ancestry.  
Results: There was weak evidence to suggest that 1 standard deviation (SD) increase in levels of 
CTACK (CCL27) (OR= 1.09 95%CI: 1.01 to 1.19, p=0.03) increased risk of Alzheimer’s disease. There 
was also weak evidence of a causal effect of 1 SD increase in levels of MIP-1b (CCL4) (OR=1.04 
95%CI: 0.99 to 1.09, p=0.08), Eotaxin (OR=1.08 95%CI: 0.99 to 1.17, p =0.10), GROa (CXCL1) 
(OR=1.04 95%CI: 0.99 to 1.10, p=0.15), MIG (CXCL9) (OR=1.17 95%CI: 0.97 to 1.41, p=0.10), IL-
8 (Wald Ratio: OR=1.21 95%CI: 0.97 to 1.51, p=0.09) and IL-2 (Wald Ratio: OR=1.21 95%CI: 0.94 
to 1.56, p=0.14) on greater risk of Alzheimer’s disease. There was little evidence of a causal effect of 
genetic liability to Alzheimer’s disease on circulating cytokine concentrations. 
Conclusions: Our study provides some evidence supporting a causal role of cytokines in the 
pathogenesis of Alzheimer’s disease. However, more studies are needed to elucidate the specific 
mechanistic pathways via which cytokines alter the risk of Alzheimer’s disease.
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 It has been estimated that 47 million people are affected by Alzheimer’s disease and other forms 
of dementia worldwide and this number is likely to increase, mostly due to ageing of the population (1). 
Thus, dementia is a major public health challenge and priority.  
Over the last decade attention has been drawn to the interplay between the central nervous 
system (CNS) and immune responses (i.e. neuroinflammation) (2) in the pathogenesis of Alzheimer’s 
disease, mostly due to evidence stemming from observational studies suggesting that inflammatory 
disorders (e.g. rheumatoid arthritis) (3) and chronic inflammation (e.g. periodontitis) (4) are associated 
with a higher risk of Alzheimer’s disease. The neuroinflammation hypothesis suggests that in response 
to production and deposition of Aβ in the brain, the CNS activates microglia to protect the cells and 
overall brain function. As part of this defense mechanism, secondary inflammatory mediators such as 
cytokines (5, 6), lipid metabolites and free radicals are generated to rehabilitate the homeostasis and 
ensure a healthy neural function (7). However, over-activation of microglia may occur and lead to an 
exaggerated release of pro- and anti-inflammatory mediators (8), resulting in deterioration or even 
initiation of neurological diseases.  
Many observational studies have examined the association between cytokine concentrations 
and risk of Alzheimer’s disease. A recent meta-analysis of 170 studies reported elevated peripheral 
levels of C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-1 beta (IL-1β), soluble tumour 
necrosis factor receptor 1 and 2 (sTNFR-1 & sTNFR-2), interleukin-10 (IL-10), monocyte 
chemoattractant protein-1 (MCP-1) and transforming growth factor-1 (TGF-1) in individuals with an 
Alzheimer’s disease diagnosis compared to healthy controls (9). However, deciphering the role of 
inflammatory markers in the pathogenesis of Alzheimer’s disease is challenging because of the potential 
bias due to reverse causation, which refers to the possibility of Alzheimer’s disease being the cause 
rather than the consequence of inflammation. Confounding is another key source of bias inherent in 
existing observational studies, as Alzheimer’s disease patients tend to be older, and thus are more at 
risk of conditions such as obesity and hypertension, which may increase systemic inflammation.    
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A promising method that could help overcome the limitations of observational studies is 
Mendelian randomization (MR). Mendelian randomization uses genetic variants as proxies for an 
exposure and allows investigation of the causal effect of the exposure on the outcome of interest (10, 
11). Moreover, two-sample MR studies, where the effect estimates of the genetic variants of exposure 
and outcome are extracted from different genome-wide association studies (GWAS) (12) can be useful, 
as they allow the estimation of causal effects without requiring the exposure and outcome to be 
measured in the same participants. Deciphering the causal role of neuroinflammation in the 
pathogenesis of Alzheimer’s disease could provide valuable information towards possible therapeutic 
targets. However, to date, very few studies have used MR to examine this question (13-16), and existing 
MR studies have included only a small, select group of previously implicated cytokines such as TNF-
a, interleukins and CRP. Considering the plethora of observational evidence indicating a role of 
cytokines in the pathogenesis of Alzheimer’s disease and the limitations of observational studies to infer 
causality, we aimed to examine the bidirectional causal effects of cytokines on risk of Alzheimer’s 
disease in a MR framework.  
METHODS 
GWAS Summary Data 
 We used the most comprehensive and largest publicly available GWAS meta-analysis on 
concentrations of 41 circulating cytokines including up to 8,293 individuals from three independent 
population cohorts (The Cardiovascular Risk in Young Finns Study (YFS), FINRISK 1997 and 
FINRISK 2002)(17). Cytokines GWAS were adjusted for sex, age and body mass index (BMI).  
For Alzheimer’s disease the most recently conducted GWAS was used, which consists of three 
phases. In phase one, 24,087 clinically diagnosed cases from the International Genomics of Alzheimer’s 
Project (IGAP), the Alzheimer’s Disease Sequencing Project (ADSP) and the Alzheimer’s disease 
working group of the Psychiatric Genomics Consortium (PGZ-ALZ) and 55,058 matched controls were 
included. In phase two, cases consist of 47,793 proxy-cases as defined in the UK Biobank and 328,320 
proxy-controls (18). Participants were considered proxy-cases if they had positively responded to the 
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question ‘Has your mother or father ever suffered from Alzheimer’s disease/Dementia’. Finally, phase 
three is a meta-analysis of all individuals in phase one & two and therefore consists of 71,880 cases and 
383,378 controls of European ancestry. In our main analysis, we used data from phase one. As these 
summary data were not publicly available, we used summary estimates from Korologou- Linden et al. 
(19), which corresponds to phase one of the Alzheimer’s GWAS. Effect estimates were adjusted for 
sex, age, genotyping array and assessment centre. This study, assessed the effect of genetic liability to 
Alzheimer’s disease on circulating cytokine concentrations, as captured by common genetic variants.  
When examining binary exposures in MR settings, causal inferences are valid for the continuous 
liability underlying the binary exposure (20). Thus, when we test for the causal effect of Alzheimer’s 
disease, we are essentially examining the effect of genetic liability for this exposure which can be 
present in an individual even when they do not have a diagnosis.  
Instrument selection 
For each exposure of interest, approximately independent genome-wide significant single 
nucleotide polymorphisms (SNPs) were identified (r2<0.01 within a 10,000 kb window, p<5×10-08). 
Eight cytokines had no SNPs available at the genome wide significance threshold, thus we relaxed the 
significance threshold to p<5×10-07 for these. When investigating the causal effects of cytokine 
concentrations on Alzheimer’s disease, we extracted the SD-scaled effect sizes and standard errors for 
cytokine SNPs from the publicly available cytokine GWAS, and corresponding log odds and standard 
errors from the Alzheimer’s disease GWAS. When investigating the reverse direction, we extracted log 
odds and standard errors for Alzheimer’s disease SNPs from the Alzheimer’s GWAS and corresponding 
SD-scaled effect sizes and standard errors from the cytokines GWAS.  
Before estimating total causal effects, we harmonised the alleles of our datasets and further 
information about the procedure followed can be found in Supplementary Note 1. 
Mendelian randomization analysis 
Univariable MR was employed to estimate the total causal effect of each circulating cytokine 
concentration on Alzheimer’s disease, and vice versa. MR relies on three assumptions that the genetic 
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variants should satisfy to be considered as valid instruments and therefore yield unbiased causal effect 
estimates. Genetic variants i) must be strongly associated with the exposure of interest, ii) independently 
of any confounders of the exposure – outcome association and iii) they are associated with the outcome 
only via the exposure (i.e. no horizontal pleiotropy) (21). 
When a single variant was available as a proxy for the exposure of interest, the Wald ratio 
estimator was employed to quantify the causal effect. When multiple variants were available, the 
Inverse-Variance-Weighted (IVW) method was used to estimate the total causal effect, which is 
equivalent to fitting a weighted linear regression of the gene-outcome associations on the gene-exposure 
associations, with the intercept term constrained to zero. Therefore, IVW estimates assume that all 
genetic variants are valid instruments with no pleiotropic effects (22, 23).  
Sensitivity analyses 
 We performed a series of sensitivity analyses to test the validity of the core assumptions which 
MR relies on (Table 1). A more comprehensive description of these sensitivity analyses can be found 
in Supplementary Note 2 and Supplementary Note 3.  
Table 1. Description of sensitivity analyses conducted, and the theoretical context of each analysis. 
Sensitivity analysis Theoretical context of each method Reference 
F statistic Genetic variant strongly associated with exposure of interest (24) 
MR-Egger Adjusting for horizontal pleiotropic effects of genetic variants (25) 
Weighted median 50% of the genetic instruments are invalid (26) 
Leave-one variant out  Pleiotropic effects of variants (27) 
Cohran’s Q Heterogeneity of genetic effects – pleiotropic effects  (25) 
Steiger filtering Hypothesized causal direction for each SNP (28) 
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Analyses including proxy cases of Alzheimer’s disease in UKB 
The main analysis was conducted using summary data from phase one of the Alzheimer’s 
disease GWAS, which included only clinically diagnosed cases. To increase the statistical power of our 
analysis, we re-ran our analysis using summary data from phase three of Alzheimer’s GWAS, which 
includes proxy cases as defined in UKB (18). The decision to use phase three as a sensitivity analysis 
rather than as main analysis, was based on the following arguments: i. UK Biobank ‘cases’ included in 
this meta-analysis were not themselves diagnosed with Alzheimer’s disease (rather, it refers to the 
participants’ parent), ii. Cases are not doctor diagnosed but based on self-report and iii. The question 
asks about broad dementia, not specifically Alzheimer’s disease.  
RESULTS 
Selection of instruments & instrument strength 
 Out of the 41 cytokines we aimed to explore, 26 of them had at least one genetic variant 
available at the genome-wide significant threshold p<5×10-08 for use in our MR analyses. For an 
additional 8 cytokines, genetic variants were available at a more liberal threshold of p<5×10-07. For 
Alzheimer’s disease 29 genetic variants were available at the genome-wide significant threshold 
p<5×10-08, 26 of which were available in the cytokines GWAS. Additional information about the 
genetic instruments used in our analyses can be found in Table S1-S2. Notably, all selected instruments 
for cytokine concentrations and Alzheimer’s disease demonstrated an F-statistic larger than 10, 
indicating that weak instruments bias is unlikely to bias our results. Information on the number of 
instruments identified for each cytokine concentration, the threshold used for selecting instruments and 
the cumulative F-statistic per cytokine can be found in Table 2. Lastly, four genetic variants were 
identified as genetic instruments for more than one cytokine and Figure 1 illustrates the overlap.  All 
these variants were included in our main analyses and their influence on our results was further explored 
in leave – one out analyses.
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Table 2. Descriptive table of the number of participants for each circulating cytokine concentration, number of instruments identified for each cytokine, 
the threshold used for selecting instruments and the cumulative F-statistic  
Cytokine 
 abbreviation 
Cytokine full name N** No. of genetic 
instruments 
Cumulative F-statistic 
IL-6* Interleukin-6 8,189 2 57.4 
IL-17 Interleukin-17 7,760 1 38.9  
MCP1 (CCL2) Monocyte chemotactic protein 1 8,293 4 422.5 
MIP1b (CCL4) Macrophage inflammatory protein-1b 8,243 25 2690.8 
GROa (CXCL1) Growth regulated oncogene-alpha 3,505 2 434.8 
IFNg* Interferon gamma 7,701 1 27.6  
IL-4* Interleukin-4 8,124 2 51.5 
IL-10 Interleukin-10 7,681 2 336.4 
IL-13 Interleukin-13 3,557 2 322.9 
IL-7 Interleukin-7 3,409 1 169.8  
IL-2ra Interleukin-2 receptor alpha 3,677 1 167.6 
IL12p70 Interleukin-12p70 8,270 3 637.9 
IL-16 Interleukin-16 3,483 3 203.6 
IL-18 Interleukin-18 3,636 4 267.8 
CTACK (CCL27) Cutaneous T-cell attracting 3,631 4 261.9 
Eotaxin Eotaxin 8,153 5 425.3 
HGF Hepatocyte growth factor 8,292 2 98.0 
IP10 Gamma-induced protein 10 3,685 1 31.1 
PDGFbb Platelet derived growth factor BB 8,293 7 549.1 
SCF Stem cell factor 8,290 2 80.4 
SCGFb Stem cell growth factor-beta 3,682 5 321.1 
TNFb Tumour necrosis factor-beta 1,559 2 130.8 
TRAIL TNF-related apoptosis inducing ligand 8,186 10 1484.7 
VEGF Vascular endothelial growth factor 7,118 9 1153.0 
MIG (CXCL9) Monokine induced by interferon- gamma 3,685 1 42.3 
RANTES (CCL5) Regulated on Activation, Normal T Cell Expressed and Secreted 3,421 1 29.9 
IL-1ra* Interleukin -1 receptor alpha 3,638 2 53.40 
IL-2* Interleukin-2 3,475 1 28.2 
IL-5 Interleukin-5 3,364 1 37.9 
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IL-8* Interleukin-8 3,526 1 25.8 
IL-9* Interleukin-9 3,634 1 25.5 
MCP3* Monocyte specific chemokine 3 843 1 25.6 
bNGF beta nerve growth factor 3,531 1 36.5 
MCSF Macrophage colony-stimulating factor  840 1 31.6 
* No genetic variants were available at the p<5×10-08 threshold. Thus, genetic variants were identified using a more liberal threshold of p<5×10-07. 
** Number of participants included in the GWAS of each cytokine concentration. 
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Figure 1. Graphical presentation of the number of genetic variants overlapping between cytokines  
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Causal effects of circulating cytokine concentrations on risk of Alzheimer’s disease 
 Overall, there was little evidence to support a causal effect of greater levels of circulating 
cytokines on risk of Alzheimer’s disease (Figure 2A-2C). Exception was CTACK (CCL27), where we 
observed weak evidence of a causal effect on Alzheimer’s disease (IVW: OR per 1 standard deviation 
(SD) increase =1.09 95%CI: 1.01 to 1.19, p=0.03). We also observed weak evidence of a causal effect 
of 1 SD increase in concentrations of MIP-1b (CCL4) (IVW: OR=1.04 95%CI: 0.99 to 1.09, p=0.08) 
and Eotaxin (IVW: OR=1.08 95%CI: 0.99 to 1.17, p =0.10) on risk of Alzheimer’s disease. 
Additionally, weak evidence was observed for an adverse effect of 1 SD increase in levels of GROa 
(CXCL1) (IVW: OR=1.04 95%CI: 0.99 to 1.10, p=0.15), MIG (CXCL9) (Wald Ratio: OR=1.17 
95%CI: 0.97 to 1.41, p=0.10), IL-8 (Wald Ratio: OR=1.21 95%CI: 0.97 to 1.51, p=0.09) and IL-2 (Wald 
Ratio: OR=1.21 95%CI: 0.94 to 1.56, p=0.14). 
Sensitivity analyses 
When more than three genetic instruments were available and MR-Egger and Weighted median 
could be estimated, we observed comparable results to the IVW. More specifically, for the cytokines 
we observed evidence for a causal effect of cytokines on Alzheimer’s disease, MR-Egger and Weighted 
median estimators yielded similar effect estimates to the IVW estimator (CTACK: MR-Egger slope: 
OR=0.99 95%CI: 0.83 to 1.17, p=0.88; Weighted median: OR=1.10 95%CI: 1.01 to 1.20, p =0.03; MIP-
1b: MR-Egger slope: OR=1.02 95%CI: 0.95 to 1.11, p =0.58; Weighted median: OR=1.01 95%CI: 0.95 
to 1.07, p =0.82; Eotaxin: MR-Egger slope: OR=1.06 95%CI: 0.86 to 1.31, p =0.58; Weighted median: 
OR=1.11 95%CI: 1.00 to 1.24, p =0.05). 
There was no indication of heterogeneity as estimated by Cochran’s Q statistic and after 
iteratively removing genetic variants results remained virtually the same in the leave-one-out analysis 
(see Supplementary material Figure S1-S20). Steiger filtering suggested that none of the genetic 
variants used as instruments for cytokines explained more variation in the outcome, thus the larger 
sample size of the Alzheimer’s disease GWAS was unlikely to have affected our results and the 
direction of effects was correctly estimated.   
 . CC-BY 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 




When we restricted our analyses to variants located in closest proximity to the encoding gene 
of each cytokine, we obtained at least one cis variant for 11 cytokines that were initially included in our 
main analysis. Overall, results remained virtually the same, but with wider confidence intervals, as a 
smaller number of instruments was included (Table S3). For greater levels of the TRAIL cytokine we 
observed weak evidence of a detrimental effect (Wald Ratio: OR=1.23 95%CI: 0.97 to 1.55, p=0.07) 
on Alzheimer’s disease.  
Analyses including proxy cases of Alzheimer’s disease in UKB 
Overall, there was limited evidence to suggest a causal effect of circulating cytokine 
concentrations on risk of Alzheimer’s disease (Supplementary Figures S21A-S21C).  As the sample 
size increased significantly with the addition of proxy-cases, confidence intervals were narrower 
compared to analyses including only cases of Alzheimer’s disease. For  IL-2, a detrimental causal effect 
on Alzheimer’s disease risk was observed (Wald Ratio: OR per 1 SD increase =1.03 95%CI: 1.00 to 
1.06, p=0.04), although the effect estimate was much smaller in magnitude compared to analyses 
including only diagnosed cased of Alzheimer’s disease.  
Causal effects of genetic liability to Alzheimer’s disease on circulating cytokine concentrations 
There was limited evidence to suggest a causal effect of genetic liability to Alzheimer’s disease 
on higher levels of circulating cytokine concentrations (Supplementary Figures 22A-22E). However, 
weak evidence was observed for a causal effect of genetic liability to Alzheimer’s disease on increased 
levels of circulating SCGFb (IVW: β= -0.06 95%CI: -0.12 to 0.01, p=0.08). 
Sensitivity analyses 
Overall, MR-Egger and Weighted median yield similar results to IVW estimators. Additionally, 
there was no indication of heterogeneity as estimated by Cochran’s Q statistic and leave-one-out 
analysis did not indicate any genetic variants as influential. 
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Analyses including proxy cases of Alzheimer’s disease in UKB 
When we included the proxy-cases of Alzheimer’s disease in our analysis we observed limited 
evidence to suggest a causal effect of genetic liability to Alzheimer’s disease on circulating cytokine 
concentrations (Supplementary Figures S22A-S22E). However, the causal effect of genetic liability to 
Alzheimer’s disease on SCGFb concentrations was confirmed (IVW: β= -0.74 95%CI: -1.16 to -0.33, 
p<0.01). Notably, the estimated causal effect was greater in magnitude.  
DISCUSSION  
Within a two-sample MR framework, we investigated the effect of 34 circulating cytokine 
concentrations on Alzheimer’s disease risk, and vice versa. We observed some evidence for a 
detrimental effect of greater levels of CTACK (CCL27), MIP-1b (CCL4), Eotaxin, GROa (CXCL1), 
MIG (CXCL9), IL-8 and IL-2 on the risk of Alzheimer’s disease. In the reverse direction, we observed 
some evidence to suggest a causal effect of genetic liability to Alzheimer’s disease only on levels of 
SCGFb. 
Very few studies have examined the causal effects of circulating cytokine concentrations of 
Alzheimer’s disease risk. Previous two-sample MR studies have investigated the causal role of a few 
cytokines ( TNF-a, IL-18, IL-1ra, IL-6) on risk of Alzheimer’s disease (13-16) and reported limited 
evidence to support a causal role. In our study we used a larger GWAS of Alzheimer’s disease, thus 
increasing statistical power to observe causal effects. Despite the increased statistical power, our results 
were in line with these findings suggesting there is little evidence of a causal effect of circulating 
cytokines on risk of Alzheimer’s disease. Notably, none of the previous two-sample MR studies have 
investigated the causal effect of genetic liability of Alzheimer’s disease on increased levels of cytokines.  
Chemokines are cytokines which regulate immune cell migration and are thought  to be mediators 
of the peripheral monocytes into the inflamed CNS (30), thus are hypothesized to be involved in the 
pathogenesis of Alzheimer’s disease (31). CTACK (CCL4), MIG (CXCL9), GROa (CXCL1), MIP-1b 
(CCL4), Eotaxin (CCL11) and IL-8 belong to the chemokine family and evidence suggest that they 
could potentially play a role in Alzheimer’s disease. More specifically, CTACK (CCL27) is a 
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chemokine involved in the CNS as it is expressed in the cerebral cortex and limbic regions which are 
mainly affected in Alzheimer’s disease (32). Previous studies have observed higher levels of circulating 
CTACK (CCL27) in Alzheimer’s disease  patients compared to healthy controls (33, 34). However, 
future research is required to better characterise the role of CTACK (CCL27) in Alzheimer’s disease 
aetiology.  
MIG (CXCL9) is another chemokine that is considered to play a role in the interplay between 
neurons and glial cells, and binds onto the CXCR3 receptor which has been previously reported to be 
involved in the pathogenesis of various CNS conditions (e.g. multiple sclerosis, glioma, bipolar 
disorder) (35, 36). Regarding Alzheimer’s disease, a cross-sectional study reported substantially higher 
levels of circulating MIG (CXCL9) in patients with Alzheimer’s disease compared to non-cognitively 
impaired and mildly-cognitively impaired participants (34). Additionally, a recent case-control study 
demonstrated evidence for an association between higher levels of MIG and Alzheimer’s disease in a 
Mexican population (33).  
A case-control study found that GROa (CXCL1) is overexpressed in the brains of 23 Alzheimer’s 
disease patients, with no prior diagnosis of immunological diseases, hypertension, cardiac disease or 
diabetes, compared to age-matched controls (37). This result is supported by animal studies, where 
CXCL1 was found to drive the hypermethylation of Tau in the primary cortical neurons of mice (38, 
39). This is supporting to our findings and together, it suggests a plausible causal role of CXCL1 in the 
pathogenesis of Alzheimer’s disease. 
Xia et al. reported that receptors of MIP-1b (CCL4) were present on microglia and subpopulation 
of reactive astrocytes and neurons in brains of patients with Alzheimer’s disease compared to controls, 
thus they could potentially play a role in the progression of Alzheimer’s disease through glial-glial and 
glial-neuronal interactions (40). Moreover, higher levels of MIP-1b has been associated with cognitive 
decline in patients with Alzheimer’s disease (41). Additionally, several studies have reported that 
expression of CCL4 is greater in brains of HIV-infected patients with dementia compared to HIV-
infected patients without dementia, which indicates that CCL4 possibly regulates an inflammatory 
process that indirectly affects neurons (42-44).  
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Higher levels of Eotaxin were identified in the cerebrospinal fluid and serum of Alzheimer’s disease 
cases compared to healthy controls (41, 45, 46). In contrast, in two cohort studies, higher levels of 
Eotaxin in the plasma were not associated with Alzheimer’s disease progression (47, 48). However, all 
the studies are of small sample size and thus underpowered to identify associations.   
Evidence regarding the role of IL-8 in the Alzheimer’s disease pathogenesis is contradicting. A 
case-control study observed elevated levels of IL-8 in the CSF of Alzheimer’s disease patients 
compared to non-demented controls (41), when another case-control study reported significantly lower 
levels in both serum and CSF of Alzheimer’s disease patients (49). Additionally, IL-8 plasma and CSF 
levels have been found to be associated with higher levels of p-tau and with higher levels of CSF Aβ1-
42, which are hallmarks of Alzheimer’s disease (50). However, evidence stems from studies with 
limited number of participants and further research is required to elucidate the role of these chemokines 
in the pathogenesis and progression of Alzheimer’s disease. 
Strengths & limitations 
 The main strength of the present study is the use of two-sample MR which could aid in 
overcoming the drawbacks of traditional observational epidemiology (i.e. reverse causation, residual 
confounding), thus allowing the estimation of the effect size of the association between circulating 
cytokines and Alzheimer’s disease. Additionally, the plethora of cytokines which we could identify 
instruments for allowed us to explore causal associations between cytokine concentrations and 
Alzheimer’s disease. Following an agnostic approach could be beneficial in this setting as limited 
observational evidence exists for most of the studied cytokines. We also used the largest GWAS study 
of Alzheimer’s disease, which included 24,087 clinically diagnosed cases and thus, our study had 
statistical power to identify causal effects. The power to detect an odds ratio of 1.1 per 1 – SD increase 
in circulating cytokine concentration, with a = 0.05 and a coefficient of determination (R2) of 3% to 
6%, was between 60% and 80%.  
There are a few limitations of this study. As few of the genetic variants used in our MR analyses 
were used as instruments for more than one cytokine, we cannot exclude the possibility that our results 
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were biased due to horizontal pleiotropic effects. We addressed this issue by estimating the total causal 
effects with alternative MR methods (MR- Egger and weighted median). Even though results remained 
virtually the same we could not completely exclude the possibility of pleiotropic effects as these 
methods are not reliable when a limited number of genetic variants is available, which is the case for 
many of the cytokines investigated.  
Moreover, cytokines are complex in their activity as they act pleiotropically (i.e. single cytokine 
acts on several different cell types), are redundant in their activity (i.e. same process might be activated 
by multiple cytokines) and can act either synergistically or antagonistically (51). This complex activity 
of cytokines raises two main issues in our study. The first issue is the possibility that the observed causal 
effects are either confounded or mediated by one or more cytokines, and therefore not representing the 
direct causal effect of each cytokine (i.e. the causal effect after taking into account the causal effect of 
all other cytokines that might mediate or confound the observed total causal effect). A future direction 
in deciphering the direct causal effects of cytokines on risk of Alzheimer’s disease would be the 
employment of multivariable Mendelian randomization, which allows the estimation of direct causal 
effects (52, 53). MVMR could be used either by including cytokines which belong in the same structural 
family (i.e. chemokines, interleukins, haemopoietins, chemokines, interferons, TNF family, colony 
stimulating factors) in a single model or based on their anti/pro-inflammatory activity. However, we 
were not able to implement MVMR mostly due to the presence of correlation between the estimated 
genetic effects of the inflammatory markers, as they were obtained from the same participants. 
Additionally, the limited number of genetic instruments available for each cytokine would have resulted 
in weak instrument bias and would have limited the statistical power to identify direct effects in the 
MVMR framework (54). The second issue is that in our analyses we assume no gene-gene or gene-
environment interactions and thus modelling the interplay between the multiple inflammatory markers 
examined is not feasible.  
Lastly, observed causal effects might be the consequence of collider bias. Collider bias occurs 
when conditioning on a variable that is affected by both exposure and outcome and could lead to 
spurious associations (55, 56). In our study, the GWAS used to extract instruments for cytokine 
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concentrations was adjusted for BMI, which is affected by both cytokines and Alzheimer’s disease, thus 
it could be considered as a collider. However, this is unlikely to affect our results as individuals on the 
cytokines GWAS were not selected based on their BMI measurement.  
CONCLUSION 
In a two-sample MR framework we observed some evidence to support a causal role of 
cytokines in the pathogenesis of Alzheimer’s disease. More studies are needed to elucidate the specific 
mechanistic pathways that underlie this process. Better understanding of these processes could 
potentially lead to novel therapeutic targets for affected individuals. 
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Figure 2A. Total causal effect of genetically predicted cytokine concentrations on the risk of Alzheimer’s disease, 
as estimated by Wald Ratio, IVW, MR-Egger and Weighted median estimators. 
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Figure 2B. Total causal effect of genetically predicted cytokine concentrations on the risk of Alzheimer’s disease, 
as estimated by Wald Ratio, IVW, MR-Egger and Weighted median estimators. 
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Figure 2C. Total causal effect of genetically predicted cytokine concentrations on the risk of Alzheimer’s disease, 
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